{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:30:42Z","timestamp":1751362242818,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Med Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200\u00a0mg\/ml ampoule dosing of ribavirin a daunting task to administer, especially during disease outbreaks. This commentary highlights the challenges and makes a passionate call for vial dosage adjustment to fit the high-dose requirement of Lassa fever disease.<\/jats:p>","DOI":"10.1186\/s41182-024-00609-0","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T08:02:00Z","timestamp":1720425720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Addressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge"],"prefix":"10.1186","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8951-7705","authenticated-orcid":false,"given":"Qudus Olajide","family":"Lawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Okoeguale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastine Oseghae","family":"Oiwoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ThankGod","family":"Akhigbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuben Agbons","family":"Eifediyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvanus Akhalufo","family":"Okogbenin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"609_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","volume":"80","author":"S Crotty","year":"2002","unstructured":"Crotty S, Cameron C, Andino R. Ribavirin\u2019s antiviral mechanism of action: lethal mutagenesis? J Mol Med (Berl). 2002;80:86\u201395.","journal-title":"J Mol Med (Berl)"},{"key":"609_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.coviro.2014.04.011","volume":"8","author":"S Beaucourt","year":"2014","unstructured":"Beaucourt S, Vignuzzi M. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation Molecular basis of ribavirin resistance. Curr Opin Virol. 2014;8:10.","journal-title":"Curr Opin Virol"},{"key":"609_CR3","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1007\/s12325-022-02256-5","volume":"39","author":"S Tejada","year":"2022","unstructured":"Tejada S, Martinez-Reviejo R, Karakoc HN, et al. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis. Adv Ther. 2022;39:4037\u201351.","journal-title":"Adv Ther"},{"key":"609_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4254\/wjh.v8.i2.123","volume":"8","author":"V Loustaud-Ratti","year":"2016","unstructured":"Loustaud-Ratti V, Debette-Gratien M, Jacques J, et al. Ribavirin: past, present and future. World J Hepatol. 2016;8:123.","journal-title":"World J Hepatol"},{"key":"609_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","volume":"314","author":"JB McCormick","year":"1986","unstructured":"McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314:20\u20136.","journal-title":"N Engl J Med"},{"key":"609_CR6","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.14797","author":"A Alli","year":"2021","unstructured":"Alli A, Ortiz JF, Fabara SP, et al. Management of lassa fever: a current update. Cureus. 2021. https:\/\/doi.org\/10.7759\/CUREUS.14797.","journal-title":"Cureus."},{"key":"609_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3126\/ijosh.v13i3.44269","volume":"13","author":"E Ogbaini-Emovon","year":"2023","unstructured":"Ogbaini-Emovon E, Erah F, Osagiede EF, et al. Lassa fever infection among healthcare workers during the 2018 outbreak in Nigeria. Int J Occup Saf Heal. 2023;13:272\u201381.","journal-title":"Int J Occup Saf Heal"},{"key":"609_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/FPUBH.2019.00170","author":"GO Akpede","year":"2019","unstructured":"Akpede GO, Asogun DA, Okogbenin SA, et al. Caseload and case fatality of lassa fever in Nigeria, 2001\u20132018: a specialist center\u2019s experience and its implications. Front Public Health. 2019. https:\/\/doi.org\/10.3389\/FPUBH.2019.00170.","journal-title":"Front Public Health"},{"key":"609_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PNTD.0010289","author":"AP Salam","year":"2022","unstructured":"Salam AP, Duvignaud A, Jaspard M, et al. Ribavirin for treating Lassa fever: a systematic review of pre-clinical studies and implications for human dosing. PLoS Negl Trop Dis. 2022. https:\/\/doi.org\/10.1371\/JOURNAL.PNTD.0010289.","journal-title":"PLoS Negl Trop Dis"},{"key":"609_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac578","volume":"76","author":"M Groger","year":"2023","unstructured":"Groger M, Akhideno P, Kleist CJ, et al. Pharmacokinetics of ribavirin in the treatment of lassa fever: an observational clinical study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria. Clin Infect Dis. 2023;76: e841.","journal-title":"Clin Infect Dis"}],"container-title":["Tropical Medicine and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-024-00609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41182-024-00609-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-024-00609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T08:09:51Z","timestamp":1720426191000},"score":1,"resource":{"primary":{"URL":"https:\/\/tropmedhealth.biomedcentral.com\/articles\/10.1186\/s41182-024-00609-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["609"],"URL":"https:\/\/doi.org\/10.1186\/s41182-024-00609-0","relation":{},"ISSN":["1349-4147"],"issn-type":[{"type":"electronic","value":"1349-4147"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"2 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}